ClinicalTrials.gg
TerminatedNCT01294397Updated Jun 20, 2017Results posted

Effects of Denosumab on the Pharmacokinetics of Etanercept

A Phase 1 interventional study of Etanercept and Denosumab in Postmenopausal, Osteopenia and Rheumatoid Arthritis, sponsored by Amgen. Terminated at 2 sites in United States. Open to female participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-06-20.

Primary conditionOsteoporosisRegistry: Bone Diseases, MetabolicReclassifiedWhy we changed it
Registry
Bone Diseases, Metabolic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis
Why
  1. The study's listed conditions name Osteoporosis, a narrower term within Bone Diseases, Metabolic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Why this study was terminated
Lack of enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
45 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
56th of 64
19 · median 90
Started
2011
with 2 others
Phase 1
5 of 64
none open now
Registered
19th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 56th largest by enrollment, is one of 3 that started in 2011, is one of 5 in phase 1, and was the 19th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 45 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis based on area under the serum concentration-time curve (AUC) and maximum observed serum concentration (Cmax).

03

Conditions studied

  • Postmenopausal
  • Osteopenia
  • Rheumatoid Arthritis
  • Osteoporosis

Browse trials for

Keywords

  • Amgen
  • Phase 1
  • Postmenopausal
  • Osteopenia
  • Rheumatoid
  • Bone Mineral Density
  • Arthritis
  • Pharmacokinetics
  • Osteoporosis
04

In context

Osteoporosis Reclassified

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

This study's enrollment of 19 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (postmenopausal is defined as no vaginal bleeding or spotting for at least 12 months)
  • Low bone mineral density (BMD) as determined by screening BMD T-scores of the lumbar spine (L1 to L4), or total evaluable vertebrae (if fewer than L1 to L4), or total hip ≤ -1.0
  • Receiving a 50 mg dose of etanercept once weekly ≥ 6 months prior to screening and expected to continue etanercept treatment at this dose and frequency through end of study (EOS)
  • If currently taking methotrexate (MTX), receiving a stable dose (7.5 to 20 mg/week) of MTX ≥ 8 weeks prior to screening
  • Willing and able to take ≥ 1,000 mg elemental calcium and ≥ 400 IU vitamin D daily upon enrollment

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes; OR poorly controlled Type 2 diabetes ( (HbA1c) > 8.0% at screening; HbA1c ≤ 8.0% within 6 months of screening is acceptable if supporting laboratory documentation is available)
  • History of heart failure, coronary artery bypass graft, or cardiac arrhythmia; OR history of acute coronary syndrome
  • Comorbid disease, demyelinating disease, or hematologic abnormalities
  • History of joint replacement in hand and/or wrist; OR history of fused joint in hand and/or wrist
  • Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw; OR active dental or jaw condition that requires oral surgery, or non-healed dental/oral surgery; OR planned invasive dental procedure(s) during the course of the study
  • Previous exposure to denosumab
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Etanercept + Denosumab

    Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.

    Drug: Etanercept · Drug: Denosumab

Interventions

  • Administered by subcutaneous injection once a week

    Also known as: Enbrel®

  • Administered by subcutaneous injection

    Also known as: Prolia®

07

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-time Curve From 0 to 168 Hours (AUC0-168) for Etanercept

    The AUC0-168 of etanercept was measured when administered alone (assessed from day 1) and after administration with denosumab (assessed from day 22, 14 days after denosumab dosing, close to the time of the maximum observed denosumab serum concentration and corresponding to a time approximately 1 week after maximal pharmacodynamic (PD) effects of denosumab are attained).

    Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.

  2. Maximum Observed Serum Concentration (Cmax) of Etanercept

    Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.

Secondary outcomes

  1. Time to Maximum Serum Concentration (Tmax) of Etanercept

    Time frame: Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.

  2. Serum Denosumab Concentration

    Time frame: Prior to etanercept and denosumab dose administrations, as applicable, on days 8, 22, and 29

  3. Percent Change From Baseline in Serum C-telopeptide (sCTx) Concentrations

    Time frame: Baseline (Day 8) and Days 22, 29, 85, and 176

08

Results

Posted Jun 20, 2017

Participant flow

This study was conducted at 2 centers in the United States. The first participant enrolled on 07 March 2011; the last participant was enrolled on 15 June 2015.

Participant flow — Overall Study
MilestoneEtanercept + Denosumab
Started19
Completed17
Not completed2
Withdrew: Withdrawal by subject1
Withdrew: Administrative decision1

Outcome measures

PrimaryArea Under the Serum Concentration-time Curve From 0 to 168 Hours (AUC0-168) for Etanercept

The AUC0-168 of etanercept was measured when administered alone (assessed from day 1) and after administration with denosumab (assessed from day 22, 14 days after denosumab dosing, close to the time of the maximum observed denosumab serum concentration and corresponding to a time approximately 1 week after maximal pharmacodynamic (PD) effects of denosumab are attained).

Time frame:
Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.
Reported as:
Mean · day*μg/mL
Area Under the Serum Concentration-time Curve From 0 to 168 Hours (AUC0-168) for Etanercept
day*μg/mLEtanercept + Denosumab
Etanercept Alone (Day 1)40.8 ± 18.8
Etanercept + Denosumab (Day 22)40.4 ± 26.6
Statistical analysis
  • Etanercept + Denosumab · Least squares mean ratio of day 22/day 1: 0.96 · 90% CI 0.85 to 1.08Two one-sided tests
PrimaryMaximum Observed Serum Concentration (Cmax) of Etanercept
Time frame:
Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.
Reported as:
Mean · μg/mL
Maximum Observed Serum Concentration (Cmax) of Etanercept
μg/mLEtanercept + Denosumab
Etanercept Alone - Day 1 (n=19)8.71 ± 5.47
Etanercept + Denosumab - Day 22 (n=18)8.25 ± 5.57
Statistical analysis
  • Etanercept + Denosumab · Least squares mean ratio of day 22/day 1: 0.92 · 90% CI 0.81 to 1.05Two one-sided tests
SecondaryTime to Maximum Serum Concentration (Tmax) of Etanercept
Time frame:
Day 1 and day 22; at each time point samples were taken predose and 2, 3, 4, 5, 6 and 8 days postdose.
Reported as:
Median · days
Time to Maximum Serum Concentration (Tmax) of Etanercept
daysEtanercept + Denosumab
Etanercept Alone - Day 1 (n=19)3.0 (0.99 to 4.9)
Etanercept + Denosumab - Day 22 (n=18)2.0 (0.93 to 4.9)
SecondarySerum Denosumab Concentration
Time frame:
Prior to etanercept and denosumab dose administrations, as applicable, on days 8, 22, and 29
Reported as:
Mean · μg/mL
Serum Denosumab Concentration
μg/mLEtanercept + Denosumab
Day 8 (n=19)0.00 ± 0.00
Day 22 (n=18)5.30 ± 1.35
Day 29 (n=18)4.85 ± 1.35
SecondaryPercent Change From Baseline in Serum C-telopeptide (sCTx) Concentrations
Time frame:
Baseline (Day 8) and Days 22, 29, 85, and 176
Reported as:
Median · percent change
Percent Change From Baseline in Serum C-telopeptide (sCTx) Concentrations
percent changeEtanercept + Denosumab
Day 22 (n = 18)-32.3 (-58.7 to 0.0)
Day 29 (n = 18)-32.3 (-60.9 to 0.0)
Day 85 (n = 17)-26.2 (-60.9 to 0.0)
Day 176/End of Study (n = 19)-25.1 (-60.4 to 0.0)

Adverse events

Collected over From first dose of etenercept in the run-in period (day -28) until end of study (day 176).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etanercept 50 mg Day - 28 - Day 7—0/19 (0%)13/19 (68.4%)
Etanercept 50 mg + Denosumab 60 mg Day 8 - EOS—0/19 (0%)2/19 (10.5%)
All Subjects On-study—0/19 (0%)13/19 (68.4%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventEtanercept 50 mg Day - 28 - Day 7Etanercept 50 mg + Denosumab 60 mg Day 8 - EOSAll Subjects On-study
Upper respiratory tract infectionInfections and infestations3/190/193/19
Urinary tract infectionInfections and infestations2/190/192/19
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/190/192/19
ErythemaSkin and subcutaneous tissue disorders2/190/192/19
Eye haemorrhageEye disorders1/190/191/19
DiarrhoeaGastrointestinal disorders1/190/191/19
Haemorrhoidal haemorrhageGastrointestinal disorders1/190/191/19
Injection site erythemaGeneral disorders1/190/191/19
Injection site pruritusGeneral disorders1/190/191/19
NoduleGeneral disorders1/190/191/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Etanercept + Denosumab
Mean63.1 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Etanercept + Denosumab
Female19
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Etanercept + Denosumab
Hispanic/Latino1
Not Hispanic/Latino18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Etanercept + Denosumab
American Indian or Alaska Native0
Asian0
Black (or African American)1
Mixed race0
Native Hawaiian or Other Pacific Islander0
White18
09

Study locations

2 sites
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Dallas, Texas 75231, United States
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2011
First posted
Feb 11, 2011
Start
Mar 2011
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Jun 20, 2017
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01294397
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 11, 2011
Start date
Mar 2011
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Jun 20, 2017
Last update
Jun 20, 2017

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etanercept · Denosumab

Start the discussion